JAMES J. CONN, M.D.; R. W. KISSANE, M.D., F.A.C.P.; RUTH A. KOON, M.D., F.A.C.P.; THOMAS E. CLARK, M.D.
This content is PDF only. Please click on the PDF icon to access.
In Part I of this paper1 we reported the results of treating a series of 42 patients afflicted with the anginal syndrome with khellin (visammin) in the form of Ammivin®. The present communication is concerned with a similar series of 42 patients with angina pectoris who were treated with a brand of khellin known as Khelloyd®.† We discussed previously the history, pharmacology and clinical aspects of the drug, and this material will not be repeated.
Forty-two patients with the anginal syndrome due to arteriosclerotic heart disease were selected to receive khellin orally and/or parenterally. These patients constituted a different
CONN JJ, KISSANE RW, KOON RA, et al. THE TREATMENT OF ANGINA PECTORIS WITH KHELLIN*: PART II. Ann Intern Med. 1953;38:23–27. doi: https://doi.org/10.7326/0003-4819-38-1-23
Download citation file:
Published: Ann Intern Med. 1953;38(1):23-27.
Cardiology, Coronary Heart Disease.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use